Jada Lewis

Jada Lewis,

Professor, Deputy Director McKnight Brain Institute

Department: Department of Neuroscience
Business Phone: (352) 273-9666
Business Email: jada.lewis@ufl.edu

Teaching Profile

Courses Taught
2019-2023
GMS5905 Special Topics in Biomedical Sciences
2019
GMS6757 Introduction to Alzheimer’s Disease and Related Dementias: Clinical and Mechanistic Principles
2019
GMS6705 Functional Human Neuroanatomy
2018
GMS7980 Research for Doctoral Dissertation
2018,2023-2024
GMS7979 Advanced Research
2013,2015-2017
GMS6750 Molecular Pathobiology of Neural Disease
2011-2015
GMS6792 Neuroscience Graduate Research Seminar
2014
GMS7794 Neuroscience Seminar
2022-2024
GMS6905 Independent Studies in Medical Sciences
2023-2024
GMS6090 Research in Medical Sciences
2023-2024
GMS7795 Special Topics in Neuroscience
2024
GMS6971 Research for Master’s Thesis

Research Profile

Open Researcher and Contributor ID (ORCID)

0000-0003-0004-6597

Publications

2024
Identification and Analysis of Axolotl Homologs for Proteins Implicated in Human Neurodegenerative Proteinopathies
Genes. 15(3) [DOI] 10.3390/genes15030310.
2023
Pharmacokinetics of delta-9-tetrahydrocannabinol following acute cannabis smoke exposure in mice; effects of sex, age, and strain.
Frontiers in pharmacology. 14 [DOI] 10.3389/fphar.2023.1227220. [PMID] 37701025.
2023
Progressive tauopathy disrupts breathing stability and chemoreflexes during presumptive sleep in mice.
Frontiers in physiology. 14 [DOI] 10.3389/fphys.2023.1272980. [PMID] 37811498.
2022
Soluble brain homogenates from diverse human and mouse sources preferentially seed diffuse Aβ plaque pathology when injected into newborn mouse hosts.
Free neuropathology. 3(9) [DOI] 10.17879/freeneuropathology-2022-3766. [PMID] 35494163.
2022
TAPPing into the potential of inducible tau/APP transgenic mice
Neuropathology and Applied Neurobiology. 48(3) [DOI] 10.1111/nan.12791.
2021
Anti-tau scFvs Targeted to the Cytoplasm or Secretory Pathway Variably Modify Pathology and Neurodegenerative Phenotypes.
Molecular therapy : the journal of the American Society of Gene Therapy. 29(2):859-872 [DOI] 10.1016/j.ymthe.2020.10.007. [PMID] 33128896.
2021
Photodynamic studies reveal rapid formation and appreciable turnover of tau inclusions.
Acta neuropathologica. 141(3):359-381 [DOI] 10.1007/s00401-021-02264-9. [PMID] 33496840.
2020
Diversity in Aβ deposit morphology and secondary proteome insolubility across models of Alzheimer-type amyloidosis.
Acta neuropathologica communications. 8(1) [DOI] 10.1186/s40478-020-00911-y. [PMID] 32252825.
2020
Intracerebral Expression of AAV-APOE4 Is Not Sufficient to Alter Tau Burden in Two Distinct Models of Tauopathy.
Molecular neurobiology. 57(4):1986-2001 [DOI] 10.1007/s12035-019-01859-4. [PMID] 31903524.
2018
Analysis of spinal and muscle pathology in transgenic mice overexpressing wild-type and ALS-linked mutant MATR3
Acta Neuropathologica Communications. 6(1) [DOI] 10.1186/s40478-018-0631-0. [PMID] 30563574.
2018
Changes in proteome solubility indicate widespread proteostatic disruption in mouse models of neurodegenerative disease.
Acta neuropathologica. 136(6):919-938 [DOI] 10.1007/s00401-018-1895-y. [PMID] 30140941.
2018
Characterization of gene regulation and protein interaction networks for Matrin 3 encoding mutations linked to amyotrophic lateral sclerosis and myopathy.
Scientific reports. 8(1) [DOI] 10.1038/s41598-018-21371-4. [PMID] 29511296.
2018
Designing antibodies against LRRK2-targeted tau epitopes.
PloS one. 13(9) [DOI] 10.1371/journal.pone.0204367. [PMID] 30261006.
2018
Differential induction of mutant SOD1 misfolding and aggregation by tau and α-synuclein pathology.
Molecular neurodegeneration. 13(1) [DOI] 10.1186/s13024-018-0253-9. [PMID] 29776378.
2018
Lrrk promotes tau neurotoxicity through dysregulation of actin and mitochondrial dynamics.
PLoS biology. 16(12) [DOI] 10.1371/journal.pbio.2006265. [PMID] 30571694.
2018
Partial loss of ATP13A2 causes selective gliosis independent of robust lipofuscinosis.
Molecular and cellular neurosciences. 92:17-26 [DOI] 10.1016/j.mcn.2018.05.009. [PMID] 29859891.
2017
A KCNC3 mutation causes a neurodevelopmental, non-progressive SCA13 subtype associated with dominant negative effects and aberrant EGFR trafficking.
PloS one. 12(5) [DOI] 10.1371/journal.pone.0173565. [PMID] 28467418.
2016
Generation of a new transgenic mouse model for assessment of tau gene silencing therapies.
Alzheimer's research & therapy. 8(1) [DOI] 10.1186/s13195-016-0202-1. [PMID] 27593210.
2016
Heterogeneity of Matrin 3 in the developing and aging murine central nervous system.
The Journal of comparative neurology. 524(14):2740-52 [DOI] 10.1002/cne.23986. [PMID] 26878116.
2016
Propagation of tau pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies.
Acta neuropathologica. 131(1):27-48 [DOI] 10.1007/s00401-015-1507-z. [PMID] 26576562.
2016
RETRACTED ARTICLE: Transgenic mice overexpressing the ALS-linked protein Matrin 3 develop a profound muscle phenotype
Acta Neuropathologica Communications. 4(1) [DOI] 10.1186/s40478-016-0393-5. [PMID] 27863507.
2015
IFN-γ promotes τ phosphorylation without affecting mature tangles.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 29(10):4384-98 [DOI] 10.1096/fj.15-275834. [PMID] 26156074.
2015
Inefficient induction and spread of seeded tau pathology in P301L mouse model of tauopathy suggests inherent physiological barriers to transmission.
Acta neuropathologica. 130(2):303-5 [DOI] 10.1007/s00401-015-1444-x. [PMID] 25982997.
2015
Physiologically relevant factors influence tau phosphorylation by leucine-rich repeat kinase 2.
Journal of neuroscience research. 93(10):1567-80 [DOI] 10.1002/jnr.23614. [PMID] 26123245.
2015
Studies of alternative isoforms provide insight into TDP-43 autoregulation and pathogenesis.
RNA (New York, N.Y.). 21(8):1419-32 [DOI] 10.1261/rna.047647.114. [PMID] 26089325.
2015
Subcellular Localization of Matrin 3 Containing Mutations Associated with ALS and Distal Myopathy.
PloS one. 10(11) [DOI] 10.1371/journal.pone.0142144. [PMID] 26528920.
2014
Age-related decline in white matter integrity in a mouse model of tauopathy: an in vivo diffusion tensor magnetic resonance imaging study.
Neurobiology of aging. 35(6):1364-74 [DOI] 10.1016/j.neurobiolaging.2013.12.009. [PMID] 24411290.
2014
Divergent phenotypes in mutant TDP-43 transgenic mice highlight potential confounds in TDP-43 transgenic modeling.
PloS one. 9(1) [DOI] 10.1371/journal.pone.0086513. [PMID] 24466128.
2014
Effects of the C57BL/6 strain background on tauopathy progression in the rTg4510 mouse model.
Molecular neurodegeneration. 9 [DOI] 10.1186/1750-1326-9-8. [PMID] 24428919.
2014
ER-mitochondria associations are regulated by the VAPB-PTPIP51 interaction and are disrupted by ALS/FTD-associated TDP-43.
Nature communications. 5 [DOI] 10.1038/ncomms4996. [PMID] 24893131.
2014
Novel marker for the onset of frontotemporal dementia: early increase in activity-dependent neuroprotective protein (ADNP) in the face of Tau mutation.
PloS one. 9(1) [DOI] 10.1371/journal.pone.0087383. [PMID] 24489906.
2014
Tau promotes neurodegeneration through global chromatin relaxation.
Nature neuroscience. 17(3):357-66 [DOI] 10.1038/nn.3639. [PMID] 24464041.
2014
Therapeutic and diagnostic challenges for frontotemporal dementia.
Frontiers in aging neuroscience. 6 [DOI] 10.3389/fnagi.2014.00204. [PMID] 25191265.
2014
Understanding the Role of Progranulin in Alzheimer’s Disease
. 20(10):1099-1100
2014
Understanding the role of progranulin in Alzheimer’s disease.
Nature medicine. 20(10):1099-100 [DOI] 10.1038/nm.3712. [PMID] 25295938.
2013
Anti-tau antibodies: hitting the target.
Neuron. 80(2):254-6 [DOI] 10.1016/j.neuron.2013.10.009. [PMID] 24139027.
2013
Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited α-synuclein accumulation and age-dependent sensorimotor deficits.
Human molecular genetics. 22(10):2067-82 [DOI] 10.1093/hmg/ddt057. [PMID] 23393156.
2013
Characteristics of TBS-extractable hyperphosphorylated tau species: aggregation intermediates in rTg4510 mouse brain.
Journal of Alzheimer's disease : JAD. 33(1):249-63 [DOI] 10.3233/JAD-2012-121093. [PMID] 22941973.
2013
Conformational templating of α-synuclein aggregates in neuronal-glial cultures.
Molecular neurodegeneration. 8 [DOI] 10.1186/1750-1326-8-17. [PMID] 23714769.
2013
Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls.
Neuron. 79(6):1094-108 [DOI] 10.1016/j.neuron.2013.07.037. [PMID] 24050400.
2013
In vivo functional brain mapping in a conditional mouse model of human tauopathy (tauP301L) reveals reduced neural activity in memory formation structures.
Molecular neurodegeneration. 8 [DOI] 10.1186/1750-1326-8-9. [PMID] 23379588.
2013
LRRK2 phosphorylates novel tau epitopes and promotes tauopathy.
Acta neuropathologica. 126(6):809-27 [DOI] 10.1007/s00401-013-1188-4. [PMID] 24113872.
2013
LRRTM3 interacts with APP and BACE1 and has variants associating with late-onset Alzheimer’s disease (LOAD).
PloS one. 8(6) [DOI] 10.1371/journal.pone.0064164. [PMID] 23750206.
2013
RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia.
Proceedings of the National Academy of Sciences of the United States of America. 110(51):E4968-77 [DOI] 10.1073/pnas.1315438110. [PMID] 24248382.
2013
Robust cytoplasmic accumulation of phosphorylated TDP-43 in transgenic models of tauopathy.
Acta neuropathologica. 126(1):39-50 [DOI] 10.1007/s00401-013-1123-8. [PMID] 23666556.
2013
Thinking laterally about neurodegenerative proteinopathies.
The Journal of clinical investigation. 123(5):1847-55 [DOI] 10.1172/JCI66029. [PMID] 23635781.
2013
Unbiased screen reveals ubiquilin-1 and -2 highly associated with huntingtin inclusions.
Brain research. 1524:62-73 [DOI] 10.1016/j.brainres.2013.06.006. [PMID] 23774650.
2012
Achievements and Challenges in Creating Animal Models of Frontotemporal Dementias
Dementia and Geriatric Cognitive Disorders. 33:5-6
2012
Neuronal sensitivity to TDP-43 overexpression is dependent on timing of induction.
Acta neuropathologica. 123(6):807-23 [DOI] 10.1007/s00401-012-0979-3. [PMID] 22539017.
2012
Progranulin regulates neuronal outgrowth independent of sortilin.
Molecular neurodegeneration. 7 [DOI] 10.1186/1750-1326-7-33. [PMID] 22781549.
2012
Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage.
American journal of human genetics. 90(6):1102-7 [DOI] 10.1016/j.ajhg.2012.04.021. [PMID] 22608501.
2011
Expression of mutant TDP-43 induces neuronal dysfunction in transgenic mice.
Molecular neurodegeneration. 6 [DOI] 10.1186/1750-1326-6-73. [PMID] 22029574.
2011
Homeostatic responses by surviving cortical pyramidal cells in neurodegenerative tauopathy.
Acta neuropathologica. 122(5):551-64 [DOI] 10.1007/s00401-011-0877-0. [PMID] 21968531.
2011
Structural abnormalities in the cortex of the rTg4510 mouse model of tauopathy: a light and electron microscopy study.
Brain structure & function. 216(1):31-42 [DOI] 10.1007/s00429-010-0295-4. [PMID] 21152933.
2010
Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging.
The American journal of pathology. 177(1):311-24 [DOI] 10.2353/ajpath.2010.090915. [PMID] 20522652.
2010
Amyloid precursor protein and tau transgenic models of Alzheimer’s disease: insights from the past and directions for the future.
Future neurology. 5(3):411-420 [PMID] 20730022.
2010
Sorting out frontotemporal dementia?
Neuron. 68(4):601-3 [DOI] 10.1016/j.neuron.2010.11.014. [PMID] 21092851.
2010
Structural and functional changes in tau mutant mice neurons are not linked to the presence of NFTs.
Experimental neurology. 223(2):385-93 [DOI] 10.1016/j.expneurol.2009.07.029. [PMID] 19665462.
2010
Targeting Abeta and tau in Alzheimer’s disease, an early interim report.
Experimental neurology. 223(2):252-66 [DOI] 10.1016/j.expneurol.2009.07.035. [PMID] 19716367.
2010
Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice.
The Journal of neuroscience : the official journal of the Society for Neuroscience. 30(32):10851-9 [DOI] 10.1523/JNEUROSCI.1630-10.2010. [PMID] 20702714.
2009
Aging analysis reveals slowed tau turnover and enhanced stress response in a mouse model of tauopathy.
The American journal of pathology. 174(1):228-38 [DOI] 10.2353/ajpath.2009.080764. [PMID] 19074615.
2009
Aging is not associated with proteasome impairment in UPS reporter mice.
PloS one. 4(6) [DOI] 10.1371/journal.pone.0005888. [PMID] 19517018.
2008
A novel calcium-binding protein is associated with tau proteins in tauopathy.
Journal of neurochemistry. 106(1):96-106 [DOI] 10.1111/j.1471-4159.2008.05339.x. [PMID] 18346207.
2008
Apparent behavioral benefits of tau overexpression in P301L tau transgenic mice.
Journal of Alzheimer's disease : JAD. 15(4):605-14 [PMID] 19096159.
2008
Apparent behavioral benefits of Tau overexpression in P301L Tau transgenic miceIn vivo silencing of alpha-synuclein using naked siRNA
. 15(4):605-614
2008
Biologic models of neurodegenerative disorders.
Handbook of clinical neurology. 89:173-88 [DOI] 10.1016/S0072-9752(07)01216-X. [PMID] 18631742.
2008
In vivo imaging reveals dissociation between caspase activation and acute neuronal death in tangle-bearing neurons.
The Journal of neuroscience : the official journal of the Society for Neuroscience. 28(4):862-7 [DOI] 10.1523/JNEUROSCI.3072-08.2008. [PMID] 18216194.
2008
In vivo silencing of alpha-synuclein using naked siRNA.
Molecular neurodegeneration. 3 [DOI] 10.1186/1750-1326-3-19. [PMID] 18976489.
2007
Accumulation of pathological tau species and memory loss in a conditional model of tauopathy.
The Journal of neuroscience : the official journal of the Society for Neuroscience. 27(14):3650-62 [PMID] 17409229.
2007
Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice.
The American journal of pathology. 171(6):2012-20 [PMID] 18055549.
2006
An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice.
Proceedings of the National Academy of Sciences of the United States of America. 103(25):9673-8 [PMID] 16769887.
2006
Neurofibrillary tangle-related synaptic alterations of spinal motor neurons of P301L tau transgenic mice.
Neuroscience letters. 409(2):95-9 [PMID] 17010516.
2005
Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L).
The Journal of neuroscience : the official journal of the Society for Neuroscience. 25(46):10637-47 [PMID] 16291936.
2005
Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo.
Proceedings of the National Academy of Sciences of the United States of America. 102(19):6990-5 [PMID] 15867159.
2005
Progressive white matter pathology in the spinal cord of transgenic mice expressing mutant (P301L) human tau.
Journal of neurocytology. 34(6):397-410 [PMID] 16902761.
2005
Tau protein is cross-linked by transglutaminase in P301L tau transgenic mice.
The Journal of neuroscience : the official journal of the Society for Neuroscience. 25(5):1226-33 [PMID] 15689560.
2005
Tau suppression in a neurodegenerative mouse model improves memory function.
Science (New York, N.Y.). 309(5733):476-81 [PMID] 16020737.
2004
Apoptosis in oligodendrocytes is associated with axonal degeneration in P301L tau mice.
Neurobiology of disease. 15(3):553-62 [PMID] 15056463.
2004
CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation.
Human molecular genetics. 13(7):703-14 [PMID] 14962978.
2004
Multi-metric behavioral comparison of APPsw and P301L models for Alzheimer’s disease: linkage of poorer cognitive performance to tau pathology in forebrain.
Brain research. 1012(1-2):29-41 [PMID] 15158158.
2004
Phosphorylated p38MAPK specific antibodies cross-react with sarkosyl-insoluble hyperphosphorylated tau proteins.
Journal of neurochemistry. 90(4):829-38 [PMID] 15287888.
2004
Rapid neurofibrillary tangle formation after localized gene transfer of mutated tau.
The American journal of pathology. 164(1):347-53 [PMID] 14695347.
2004
The retinal degeneration (rd) gene seriously impairs spatial cognitive performance in normal and Alzheimer’s transgenic mice
Neuroreport. 15(1):73-77 [PMID] 15106834.
2003
Co-localization of glycogen synthase kinase-3 with neurofibrillary tangles and granulovacuolar degeneration in transgenic mice.
The American journal of pathology. 163(3):1057-67 [PMID] 12937146.
2003
Filamentous tau in oligodendrocytes and astrocytes of transgenic mice expressing the human tau isoform with the P301L mutation.
The American journal of pathology. 162(1):213-8 [PMID] 12507904.
2003
Ultrastructural neuronal pathology in transgenic mice expressing mutant (P301L) human tau.
Journal of neurocytology. 32(9):1091-105 [PMID] 15044841.
2002
Assembly of tau in transgenic animals expressing P301L tau: alteration of phosphorylation and solubility.
Journal of neurochemistry. 83(6):1498-508 [PMID] 12472903.
2001
Analysis of tauopathies with transgenic mice.
Trends in molecular medicine. 7(10):467-70 [PMID] 11597522.
2001
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP.
Science (New York, N.Y.). 293(5534):1487-91 [PMID] 11520987.
2001
Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles.
Science (New York, N.Y.). 293(5530):711-4 [PMID] 11408621.
2000
Animal Models of tau dysfunction
Neuroscience. 3(5):63-72
2000
Missense tau mutations identified in FTDP-17 have a small effect on tau-microtubule interactions.
Brain research. 853(1):5-14 [PMID] 10627302.
2000
Neurofibrillary tangles, amyotrophy, and progressive motor impairment in Tau mutant (P301L) transgenic mice
Nature Genetics. 25:402-405
2000
The molecular genetics of the tauopathies.
Experimental gerontology. 35(4):461-71 [PMID] 10959034.
1999
5′ splice site mutations in tau associated with the inherited dementia FTDP-17 affect a stem-loop structure that regulates alternative splicing of exon 10.
The Journal of biological chemistry. 274(21):15134-43 [PMID] 10329720.
1999
Accelerated filament formation from tau protein with specific FTDP-17 missense mutations
FEBS Letters. 447(2-3):195-199 [DOI] 10.1016/S0014-5793(99)00294-X. [PMID] 10214944.
1998
A common human beta globin splicing mutation modeled in mice
Blood. 91(6):2152-2156 [PMID] 9490703.
1998
Rapid genotyping of mice with hemoglobinopathies and globin transgenes.
Biochemical genetics. 36(1-2):65-77 [PMID] 9562907.
1996
Gene modification via “plug and socket” gene targeting.
The Journal of clinical investigation. 97(1):3-5 [PMID] 8550847.
1995
A mouse model for beta 0-thalassemia.
Proceedings of the National Academy of Sciences of the United States of America. 92(25):11608-12 [PMID] 8524813.
1994
Deletion and replacement of the mouse adult beta-globin genes by a “plug and socket” repeated targeting strategy.
Molecular and cellular biology. 14(10):6936-43 [PMID] 7935410.

Grants

Jul 2023 ACTIVE
Immunotherapy targeting the HPA axis in Alzheimers disease
Role: Principal Investigator
Funding: EMORY UNIV via NATL INST OF HLTH NIA
Sep 2022 ACTIVE
A Systems Approach to Targeting Innate Immunity in AD
Role: Principal Investigator
Funding: MAYO CLINIC via NATL INST OF HLTH NIA
Apr 2022 ACTIVE
Characterization of new CamK2-tau strains of mice to model dementia
Role: Principal Investigator
Funding: FL DEPT OF HLTH ED ETHEL MOORE ALZHEIMER
Feb 2022 ACTIVE
Contributions of tau-mediated translational dysregulation to pathogenesis and progression of fronto-temporal dementia
Role: Co-Investigator
Funding: NATL INST OF HLTH NIA
Sep 2021 ACTIVE
Developing new conditional models to study tauopathy, amyloidosis, and their interaction
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Aug 2021 ACTIVE
Effects of cannabis on age-related cognitive decline and Alzheimers disease pathology
Role: Co-Investigator
Funding: NATL INST OF HLTH NIA
May 2021 – Feb 2023
Effects of cannabis on Alzheimers disease-related pathology and cognitive decline
Role: Co-Investigator
Funding: FL DEPT OF HLTH ED ETHEL MOORE ALZHEIMER
Sep 2019 – Aug 2021
Developing new conditional models to study tauopathy, amyloidosis, and their interaction
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Aug 2019 ACTIVE
Elucidating factors that modulate tauopathy and cellular degeneration to guide therapeutic development
Role: Principal Investigator
Funding: NATL INST OF HLTH NIA
Aug 2019 – Jul 2022
Immunotherapy targeting the HPA axis in Alzheimers disease
Role: Principal Investigator
Funding: NATL INST OF HLTH NIA
Mar 2019 – Feb 2021
The Two Faces of Hypoxia in Alzheimer's Disease
Role: Co-Investigator
Funding: FL DEPT OF HLTH ED ETHEL MOORE ALZHEIMER
Sep 2018 ACTIVE
Clinical and Translational Pre-doctoral training in Alzheimers Disease and Related Dementias
Role: Principal Investigator
Funding: NATL INST OF HLTH NIA
Jun 2018 – Aug 2023
APOE as a modifier of prion-like spread in dementia
Role: Co-Investigator
Funding: NATL INST OF HLTH NIA
Sep 2017 – May 2018
APOE as a modifier of prion-like spread in dementia
Role: Co-Investigator
Funding: NATL INST OF HLTH NIA
Sep 2017 – Jun 2020
Uncovering targets that block pathological interactions between Abeta and tau
Role: Co-Investigator
Funding: NATL INST OF HLTH NIA
Mar 2017 – Feb 2024
Towards understanding the role of immune regulation of Apolipoprotein E function in Alzheimers disease proteostasis
Role: Co-Investigator
Funding: NATL INST OF HLTH NIA
Feb 2017 – Sep 2019
Large-scale identification of genes that suppress concurrent Abeta42 and tau pathology in vivo
Role: Co-Investigator
Funding: FL DEPT OF HLTH ED ETHEL MOORE ALZHEIMER
Dec 2016 – Nov 2019
Is there a form of benign brain amyloidosis in aging?
Role: Principal Investigator
Funding: NATL INST OF HLTH NIA
Aug 2016 – Sep 2019
New mouse models to dissect out the function of the ALS-associated protein Matrin 3
Role: Principal Investigator
Funding: AMYOTROPHIC LATERAL SCLEROSIS ASSOC
Aug 2015 – May 2021
University of Florida – Mt. Sinai Medical Center AD Research Center
Role: Co-Project Director/Principal Investigator
Funding: NATL INST OF HLTH NIA
Jul 2015 – Jun 2018
Towards a knockdown therapy for tauopathy
Role: Principal Investigator
Funding: BRIGHTFOCUS FOU
Apr 2015 – Jun 2021
Clinical and Translational Science Institute (CTSI)
Role: Project Manager
Funding: UF DIV OF SPONSORED RES MATCHING FUNDS
Jul 2014 – Jun 2017
Optogenetic modeling of primary and secondary CNS proteinopathies in Drosophila
Role: Project Manager
Funding: NATL INST OF HLTH NINDS
Apr 2014 – Mar 2016
Einstein Aging Study Neuropathology Core
Role: Principal Investigator
Funding: MAYO CLINIC via NATL INST OF HLTH
Jul 2013 – Jun 2018
Biological and Pathological Interactions between Tau and LRRK2
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Jul 2010 – Jun 2023
Animal Models in neurodegenerative Disease
Role: Principal Investigator
Funding: FL CLINICAL PRACTICE ASSO

Contact Details

Phones:
Business:
(352) 273-9666
Emails:
Business:
jada.lewis@ufl.edu
Addresses:
Business Mailing:
PO Box 100244
GAINESVILLE FL 32610
Business Street:
PO Box 100244
GAINESVILLE FL 32610